Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 45 | 2024 | 945 | 11.920 |
Why?
|
| Kidney Failure, Chronic | 42 | 2024 | 960 | 11.390 |
Why?
|
| Peritoneal Dialysis | 9 | 2023 | 125 | 5.870 |
Why?
|
| Medicare | 16 | 2023 | 860 | 2.770 |
Why?
|
| Prospective Payment System | 5 | 2021 | 17 | 2.600 |
Why?
|
| Hemodialysis, Home | 4 | 2022 | 12 | 2.110 |
Why?
|
| Ambulatory Care | 5 | 2021 | 554 | 1.950 |
Why?
|
| United States | 41 | 2023 | 15433 | 1.790 |
Why?
|
| Nephrologists | 3 | 2021 | 13 | 1.670 |
Why?
|
| Ambulatory Care Facilities | 6 | 2021 | 289 | 1.610 |
Why?
|
| Health Facility Closure | 2 | 2021 | 8 | 1.560 |
Why?
|
| Health Care Sector | 3 | 2020 | 28 | 1.500 |
Why?
|
| Renal Insufficiency | 3 | 2023 | 321 | 1.450 |
Why?
|
| Health Policy | 4 | 2020 | 291 | 1.430 |
Why?
|
| Delivery of Health Care | 5 | 2022 | 860 | 1.410 |
Why?
|
| Patient Readmission | 4 | 2017 | 548 | 1.280 |
Why?
|
| Nephrology | 3 | 2019 | 151 | 1.130 |
Why?
|
| Fee-for-Service Plans | 2 | 2016 | 40 | 1.130 |
Why?
|
| Medicaid | 6 | 2019 | 279 | 1.090 |
Why?
|
| Reimbursement Mechanisms | 3 | 2021 | 78 | 1.050 |
Why?
|
| Financing, Government | 2 | 2023 | 40 | 1.030 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 915 | 0.980 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2021 | 1303 | 0.980 |
Why?
|
| Economic Competition | 3 | 2018 | 18 | 0.960 |
Why?
|
| Health Expenditures | 4 | 2022 | 211 | 0.960 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2014 | 26 | 0.950 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2015 | 112 | 0.920 |
Why?
|
| Benzazepines | 2 | 2014 | 108 | 0.900 |
Why?
|
| National Health Programs | 1 | 2023 | 42 | 0.890 |
Why?
|
| Hospitalization | 4 | 2021 | 2083 | 0.880 |
Why?
|
| Vitamin D | 2 | 2018 | 261 | 0.880 |
Why?
|
| Registries | 8 | 2022 | 2170 | 0.820 |
Why?
|
| Accountable Care Organizations | 1 | 2020 | 12 | 0.770 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2020 | 9 | 0.740 |
Why?
|
| Health Facility Merger | 2 | 2019 | 9 | 0.740 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2020 | 787 | 0.720 |
Why?
|
| Safety-net Providers | 1 | 2019 | 53 | 0.700 |
Why?
|
| Reimbursement, Incentive | 2 | 2023 | 53 | 0.690 |
Why?
|
| Health Care Costs | 3 | 2020 | 674 | 0.680 |
Why?
|
| Humans | 62 | 2024 | 261506 | 0.680 |
Why?
|
| Insurance, Health | 2 | 2018 | 250 | 0.680 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2019 | 849 | 0.650 |
Why?
|
| Specialization | 1 | 2019 | 130 | 0.650 |
Why?
|
| Models, Organizational | 1 | 2019 | 76 | 0.650 |
Why?
|
| Nurse Practitioners | 1 | 2019 | 63 | 0.650 |
Why?
|
| Kidney Transplantation | 2 | 2021 | 755 | 0.640 |
Why?
|
| Physician Assistants | 1 | 2019 | 74 | 0.640 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 107 | 0.630 |
Why?
|
| Commerce | 1 | 2018 | 68 | 0.620 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 164 | 0.580 |
Why?
|
| Telemedicine | 1 | 2023 | 471 | 0.580 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 2195 | 0.550 |
Why?
|
| Mobility Limitation | 1 | 2015 | 31 | 0.530 |
Why?
|
| Aged | 24 | 2023 | 70117 | 0.520 |
Why?
|
| Skilled Nursing Facilities | 1 | 2015 | 13 | 0.520 |
Why?
|
| Insurance Coverage | 1 | 2017 | 256 | 0.520 |
Why?
|
| Physicians | 2 | 2023 | 882 | 0.510 |
Why?
|
| Vascular Access Devices | 1 | 2014 | 51 | 0.490 |
Why?
|
| Office Visits | 1 | 2015 | 97 | 0.490 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 585 | 0.460 |
Why?
|
| Health Resources | 1 | 2015 | 168 | 0.460 |
Why?
|
| Pravastatin | 1 | 2013 | 34 | 0.450 |
Why?
|
| Male | 32 | 2024 | 123000 | 0.450 |
Why?
|
| Rhabdomyolysis | 1 | 2013 | 52 | 0.440 |
Why?
|
| Glomerular Filtration Rate | 2 | 2013 | 602 | 0.430 |
Why?
|
| Health Care Reform | 3 | 2020 | 68 | 0.430 |
Why?
|
| Female | 32 | 2024 | 141928 | 0.420 |
Why?
|
| Middle Aged | 22 | 2024 | 86204 | 0.380 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 524 | 0.370 |
Why?
|
| Hyperparathyroidism | 1 | 2010 | 93 | 0.370 |
Why?
|
| Naphthalenes | 1 | 2010 | 83 | 0.370 |
Why?
|
| Cost-Benefit Analysis | 4 | 2019 | 945 | 0.370 |
Why?
|
| Residence Characteristics | 1 | 2013 | 348 | 0.360 |
Why?
|
| Ownership | 3 | 2019 | 40 | 0.360 |
Why?
|
| Hematinics | 1 | 2010 | 109 | 0.350 |
Why?
|
| Cohort Studies | 8 | 2019 | 9244 | 0.350 |
Why?
|
| Hemoglobins | 1 | 2010 | 477 | 0.330 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2015 | 705 | 0.310 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2013 | 226 | 0.300 |
Why?
|
| Emergency Service, Hospital | 1 | 2015 | 1148 | 0.300 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 598 | 0.300 |
Why?
|
| Cost Savings | 2 | 2020 | 123 | 0.300 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 1054 | 0.280 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 1021 | 0.280 |
Why?
|
| Multivariate Analysis | 4 | 2015 | 4298 | 0.280 |
Why?
|
| Anemia | 1 | 2010 | 689 | 0.250 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 799 | 0.250 |
Why?
|
| Stroke | 1 | 2013 | 1144 | 0.240 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 1374 | 0.230 |
Why?
|
| Time Factors | 7 | 2019 | 12926 | 0.230 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 4314 | 0.230 |
Why?
|
| Retrospective Studies | 9 | 2022 | 37905 | 0.230 |
Why?
|
| Markov Chains | 2 | 2013 | 175 | 0.220 |
Why?
|
| Travel | 1 | 2023 | 190 | 0.210 |
Why?
|
| Adult | 11 | 2022 | 77950 | 0.200 |
Why?
|
| Patient Outcome Assessment | 1 | 2023 | 245 | 0.200 |
Why?
|
| Patient Care Bundles | 1 | 2021 | 30 | 0.200 |
Why?
|
| Health Facilities, Proprietary | 1 | 2019 | 4 | 0.180 |
Why?
|
| Benzofurans | 1 | 2019 | 38 | 0.180 |
Why?
|
| China | 1 | 2021 | 606 | 0.170 |
Why?
|
| Data Collection | 1 | 2022 | 620 | 0.170 |
Why?
|
| Medically Uninsured | 1 | 2019 | 102 | 0.170 |
Why?
|
| Quinoxalines | 1 | 2019 | 95 | 0.170 |
Why?
|
| Ezetimibe | 1 | 2019 | 101 | 0.170 |
Why?
|
| Patient Care | 1 | 2020 | 149 | 0.170 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 88 | 0.160 |
Why?
|
| Propensity Score | 1 | 2021 | 750 | 0.160 |
Why?
|
| Indians, North American | 1 | 2018 | 87 | 0.160 |
Why?
|
| Policy Making | 1 | 2018 | 85 | 0.160 |
Why?
|
| Disease Progression | 3 | 2013 | 6682 | 0.150 |
Why?
|
| Central Venous Catheters | 1 | 2018 | 98 | 0.150 |
Why?
|
| Logistic Models | 2 | 2016 | 3441 | 0.150 |
Why?
|
| Outpatients | 1 | 2020 | 462 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 761 | 0.150 |
Why?
|
| Primary Health Care | 1 | 2023 | 787 | 0.150 |
Why?
|
| Employment | 1 | 2018 | 129 | 0.150 |
Why?
|
| Health Care Surveys | 1 | 2018 | 430 | 0.150 |
Why?
|
| Program Development | 1 | 2018 | 261 | 0.150 |
Why?
|
| Decision Support Techniques | 2 | 2013 | 622 | 0.140 |
Why?
|
| Physician's Role | 1 | 2019 | 238 | 0.140 |
Why?
|
| Hospitals | 1 | 2019 | 485 | 0.140 |
Why?
|
| Cause of Death | 1 | 2018 | 752 | 0.130 |
Why?
|
| Risk Factors | 4 | 2018 | 17523 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2018 | 597 | 0.130 |
Why?
|
| Heart Transplantation | 1 | 2022 | 908 | 0.130 |
Why?
|
| Graft Survival | 1 | 2018 | 1062 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 2016 | 756 | 0.120 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 451 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2022 | 32848 | 0.120 |
Why?
|
| Kidney | 4 | 2024 | 2146 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 1819 | 0.120 |
Why?
|
| Imidazoles | 1 | 2019 | 999 | 0.120 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 249 | 0.120 |
Why?
|
| Public Health | 1 | 2016 | 299 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2019 | 795 | 0.110 |
Why?
|
| Life Expectancy | 1 | 2013 | 129 | 0.110 |
Why?
|
| Heart-Assist Devices | 1 | 2022 | 1171 | 0.110 |
Why?
|
| Hypertension, Renal | 1 | 2012 | 30 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2020 | 851 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2019 | 1230 | 0.110 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 232 | 0.110 |
Why?
|
| Proteinuria | 1 | 2012 | 155 | 0.100 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2015 | 412 | 0.100 |
Why?
|
| Heparin | 1 | 2014 | 360 | 0.100 |
Why?
|
| Drug Costs | 1 | 2013 | 144 | 0.100 |
Why?
|
| Risk | 2 | 2013 | 1972 | 0.100 |
Why?
|
| Age of Onset | 1 | 2013 | 827 | 0.100 |
Why?
|
| Morbidity | 1 | 2012 | 397 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2013 | 255 | 0.100 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 2315 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2016 | 691 | 0.090 |
Why?
|
| Health Status | 1 | 2013 | 590 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2014 | 661 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2014 | 712 | 0.090 |
Why?
|
| Neoplasms | 1 | 2015 | 15193 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2016 | 806 | 0.080 |
Why?
|
| Heart Failure | 1 | 2022 | 2516 | 0.080 |
Why?
|
| Young Adult | 4 | 2019 | 21445 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2014 | 787 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2013 | 2316 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 2139 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 792 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 4938 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 4988 | 0.070 |
Why?
|
| Hypertension | 1 | 2013 | 1503 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6207 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 2992 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2023 | 556 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 29902 | 0.050 |
Why?
|
| Motivation | 1 | 2023 | 499 | 0.050 |
Why?
|
| Carbamates | 1 | 2019 | 77 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2019 | 88 | 0.040 |
Why?
|
| Amides | 1 | 2019 | 123 | 0.040 |
Why?
|
| Unemployment | 1 | 2018 | 31 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 273 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 14889 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2019 | 397 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2018 | 324 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2016 | 208 | 0.030 |
Why?
|
| Choice Behavior | 1 | 2016 | 226 | 0.030 |
Why?
|
| Patient Preference | 1 | 2016 | 218 | 0.030 |
Why?
|
| Adolescent | 3 | 2019 | 31252 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 929 | 0.030 |
Why?
|
| South Carolina | 1 | 2011 | 18 | 0.030 |
Why?
|
| Genotype | 1 | 2019 | 4109 | 0.030 |
Why?
|
| Georgia | 1 | 2011 | 53 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 2352 | 0.020 |
Why?
|
| North Carolina | 1 | 2011 | 125 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2019 | 1823 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 257 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 4320 | 0.020 |
Why?
|
| Veterans | 1 | 2019 | 1641 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 5377 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 1546 | 0.020 |
Why?
|
| Quality of Health Care | 1 | 2011 | 621 | 0.020 |
Why?
|